| Title |
New drug classes for the treatment of partial onset epilepsy: focus on perampanel
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, July 2013
|
| DOI | 10.2147/tcrm.s37317 |
| Pubmed ID | |
| Authors |
Jerry J Shih, William O Tatum, Leslie A Rudzinski |
| Abstract |
Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca(2+) and selectively blocks AMPA receptor-mediated synaptic transmission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Unknown | 122 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 13% |
| Student > Master | 14 | 11% |
| Researcher | 12 | 10% |
| Student > Postgraduate | 12 | 10% |
| Student > Ph. D. Student | 12 | 10% |
| Other | 19 | 15% |
| Unknown | 38 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 15% |
| Neuroscience | 11 | 9% |
| Agricultural and Biological Sciences | 9 | 7% |
| Chemistry | 6 | 5% |
| Other | 12 | 10% |
| Unknown | 42 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2014.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#695
of 1,308 outputs
Outputs of similar age
#117,973
of 207,028 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 9 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,028 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.